Label Promotion of Drugs and Medical Devices 2018

Overview: This session sets the context for the off-label promotion of medical products starting with early history and moving to the most recent history of FDA's decision on guidance documents. Why should you Attend: This session will discuss comments from industry, health care providers, health care insurers and other concerned parties. The latest legal considerations, decisions and conclusions will be discussed as well as future expectations for off-label promotion of medical products. Who Will Benefit: Quality Managers Quality Engineers Regulatory Affairs Regulatory Attorneys Doctors Health Insurance